Compare Electronic Arts Inc. (EA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Electronic Arts Inc. vs Viatris Inc — how do they compare? Electronic Arts Inc. trades at $207.39 (market cap $51.97B), while Viatris Inc trades at $17.33 (market cap $19.44B). The key difference: Electronic Arts Inc. is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| EA | VTRS | |
|---|---|---|
Market Cap | $51.97B | $19.44B |
Sector | Technology | Health |
52-Week High | $207.27 | $17.39 |
52-Week Low | $147.79 | $8.74 |
Enterprise Value | $50.54B | $31.65B |
Dividend Yield | 0.37% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Electronic Arts (EA) trades at $207.31, up 0.32% on the day, with a bullish technical signal from moving averages and strong support at $205. The company reported Q4 2025 EPS beat but Q1 2026 miss, with revenue stable around $7.5B and a net income margin of 11.78%. Recent launches like EA SPORTS College Football 27 and UFC 6 highlight ongoing product momentum, while a potential $55B acquisition by Saudi investors adds strategic intrigue.
Outlook remains mixed: high valuation ratios (P/E 59.05) suggest premium pricing, but robust cash flow and dividend payments support shareholder returns. Key risks include earnings volatility and competitive pressures in gaming. Analyst consensus leans Hold (56.06%), indicating cautious optimism amid execution uncertainties.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
